Where it trades today
trading 6% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- SYK trades at 28.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 38.9%, above the sector norm of 22.0%, so position sizing matters more than usual.
- SYK remains in a bearish short-term trend and sits 29.9% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- SYK is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in SYK.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for SYK come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for SYK. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Stryker Corporation does
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical…
What analysts expect
SYK carries a buy consensus from 25 analysts, with an average price target of $374.88 versus $275.12 today (+36.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
SYK generated $25.84B in trailing revenue (9.4% year over year), with a 14.4% net margin, and $4.11B of free cash flow, against $11.97B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $25.12B | $16.07B | $5.06B | $3.25B | $8.49 | $4.28B |
| 2024 | $22.59B | $14.44B | $4.67B | $2.99B | $7.86 | $3.49B |
| 2023 | $20.50B | $13.06B | $3.92B | $3.17B | $8.34 | $3.14B |
| 2022 | $18.45B | $11.58B | $3.11B | $2.36B | $6.23 | $2.04B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
SYK beside the healthcare names it is usually measured against.
What the chart is saying
Stryker Corporation trades at $275.12, 29.9% below its 52-week high. With a beta of 0.77, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is SYK a good buy right now?
Stryker Corporation trades at 28.5x earnings. This is near market average. Current risk level is High based on 38.9% volatility.
Does SYK pay dividends?
Yes, Stryker Corporation offers a dividend yield of 1.26%. That is roughly $3.47 per share a year.
How volatile is SYK?
With 30-day annualized volatility of 38.9% and beta of 0.77, SYK is classified as High risk. The stock tends to be more stable than the market average.
What is the analyst price target for SYK?
The average analyst price target for Stryker Corporation (SYK) is $374.88 based on 25 analyst estimates, about 36.3% above the current price of $275.12. The published range runs from $315.00 to $465.00.
How much revenue does SYK generate?
Stryker Corporation reported $25.84B in trailing twelve-month revenue. Revenue growth is running at 9.4% year over year. Net margin sits at 14.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.